Collaborative and Other Relationships (Details)			1 Months Ended	3 Months Ended	1 Months Ended	3 Months Ended
	Mar. 31, 2012 USD ($)	Mar. 31, 2012 KRW	Feb. 29, 2012 Samsung Bio-similar Agreement [Member] KRW	Mar. 31, 2012 Samsung Bio-similar Agreement [Member] USD ($)	Jan. 31, 2012 ISIS Pharmaceuticals [Member] USD ($)	Mar. 31, 2012 ISIS Pharmaceuticals [Member] USD ($)
Collaborations (Textual) [Abstract]
Upfront Payment					$ 29,000,000
Additional milestone payment					45,000,000
Phase 2/3 milestone payment						18,000,000
License fee					150,000,000
Milestone payments received under collaboration agreement						29,000,000
License Fee						75,000,000
Schedule of Equity Method Investments [Line Items]
Contribution from Samsung to develop, manufacture and market bio-similar pharmaceuticals			280,500,000,000
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage			85.00%
Total investment	22,100,000	24,800,000,000	49,500,000,000
Percentage of stake in entity minimum			15.00%
Percentage of stake in entity maximum			49.90%
Revenue related to technical development and technology transfer services				1,000,000
Remaining obligation of financing arrangements				$ 24,700,000